Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2019 Earnings Conference Call Transcript

Feb 07, 2019 • 04:30 pm ET


Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2019 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good afternoon. My name is Michelle, and I will be your operator for today's call. Welcome to the Anavex Life Sciences Fiscal 2019 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Mr. Scott Gordon. Please go ahead, sir.

Scott Gordon

Thank you, Michelle, and thank you, everybody, for joining us and good afternoon. We appreciate you joining us today for Anavex Life Sciences conference call and webcast. Our agenda is to review the company's financial results for the first quarter of fiscal 2019, provide a clinical study update and highlight recent corporate developments.

A taped replay of this call will be available approximately two hours after the call's conclusion and will remain available for one month. The call will also be available for replay on Anavex's website at With us today are Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer. Dr. Missling and Ms. Boenisch will make prepared remarks and then we will take questions from equity analysts. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the SEC. This includes without limitation the company's Forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital and maintenance of intellectual property rights.

And with that, it is my pleasure to now turn the call over to Dr. Missling.

Christopher Missling

Thank you. I'd like to thank everyone for joining us on today's conference call to review our fiscal 2019 first quarter financial results and share with you our clinical updates for ANAVEX 2-73. First, we are pleased to report that since enrollment started on October 30, 2018 for the Phase II ANAVEX 2-73 Parkinson's disease dementia study, we have achieved over one-third of the total patient enrollment target to date. The Company is also executing well with enrollment for the Phase IIb/III ANAVEX 2-73 Alzheimer's disease study with over 80 patients screened to date. Regarding our Rett syndrome program, we recently successfully submitted the Phase II ANAVEX 2-73 study to the respective Institutional Review Boards of the first three clinical trial sites. And we will continue to add further sites in the United States to the study in the coming months. Last month we announced the appointment of Walter Kaufmann M.D., as Chief Medical Officer of Anavex. We are very excited to have Dr. Kaufmann on our team. Dr. Kaufmann brings extensive experience in Rett syndrome and other disorders related to Anavex target indications. I'm looking forward to his involvement